Table 1 Baseline characteristics
Characteristics | Total population (N = 224) | LIPI 0 Good (N = 80,35.7%) | LIPI 1 Intermediate (N = 91, 40.6%) | LIPI 2 Poor (N = 53, 23.7%) | P value |
|---|---|---|---|---|---|
Age (years) | 52.6 ± 10.5 | 53.1 ± 13.0 | 54.9 ± 8.8 | 53.3 ± 11.2 | 0.484 |
Gender | 0.296 | ||||
Male | 182(81.3%) | 64(80.0%) | 78(85.7%) | 40(75.5%) | |
Female | 42(18.8%) | 16(20.0%) | 13(14.3%) | 13(24.5%) | |
ECOG performance status | 0.676 | ||||
0 | 152(67.2%) | 57(71.3%) | 61(67.0%) | 34(64.2%) | |
1 | 72(32.2%) | 23(28.8%) | 30(33.0%) | 19(35.8%) | |
Child–Pugh stage | 0.112 | ||||
A | 159(71.0%) | 65(81.3%) | 58(63.7%) | 36(67.9%) | |
B | 47(21.0%) | 12(15.0%) | 24(26.4%) | 11(20.8%) | |
C | 18(8.1%) | 3(3.8%) | 9(9.9%) | 6(11.3%) | |
HBV infection | 0.562 | ||||
No | 23(10.3%) | 10(12.5%) | 7(7.7%) | 6(11.3%) | |
Yes | 201(89.7%) | 70(87.5%) | 84(92.3%) | 47(88.7%) | |
Macrovascular invasion | 0.165 | ||||
No | 183(81.7%) | 68(85.0%) | 69(75.8%) | 46(86.8%) | |
Yes | 41(18.3%) | 12(15.0%) | 22(24.2%0 | 7(13.2%) | |
AFP (ng/ml) | 0.178 | ||||
< 400 | 93(42.3%) | 32(41.0%) | 33(37.1%) | 28(52.8%) | |
> 400 | 127(57.7%) | 46(59.0%) | 56(62.9%) | 25(47.2) | |
Combined with target therapy | 0.781 | ||||
Yes | 112(50.0%) | 39(48.8%) | 48(52.7%) | 25(47.2%) | |
No | 112(50.0%) | 41(51.3%) | 43(47.3%) | 28(52.8%) | |